突發政策利好!港A醫療器械股集體走強
格隆匯7月14日丨醫療器械股集體走強。A股五洲醫療漲超11%,祥生醫療漲超9%,福瑞股份漲超8%,心脈醫療漲近8%,之江生物、歐普康視、開立醫療漲超6%;港股微創醫療漲近8%,啟明醫療漲超6%,微創機器人漲超4%。北京市醫保局7月13日印發《CHS-DRG 付費新藥新技術除外支付管理辦法的通知(試行)》,決定於2022年7月20日至2022年8月19日期間開展2022年CHS-DRG付費新藥新技術除外支付申報工作。國金證券稱,除外支付申報主要針對創新性藥品、醫療器械及診療項目,切實提升臨牀效用的產品或項目將受益。國金證券指出,除外支付機制有望進一步提振創新技術積極性。在實施傳統DRG支付制度時,存在特殊病例、高成本服務項目及技術創新型項目等特殊情況,使得治療費用或資源消耗水平遠高於同組病例平均水平。將這些項目列入DRG支付制度下的除外項目,有望克服傳統DRG支付制度痛點,提高DRG病組資源消耗的同質性,使得創新性醫療項目或產品更具經濟性,在合理使用醫保基金的同時,進一步助力創新技術發展,利好創新藥械企業及創新產業鏈。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.